A month ago, Tekmira shares took a deep dive after the FDA placed a clinical hold on its Ebola therapy, the RNAi therapy TKM-Ebola, citing concerns about cytokine release–a condition which can spur a fatal noninfectious fever in the worst cases. The Canadian biotech’s shot up more than 12% on Monday morning on speculation that the FDA would put the treatment back on its fast track.

…read more

Source: Biotechs find themselves in R&D spotlight as Ebola hits the headlines


0 No comments